ICU vs RNAZ

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 24, 2026

ICU

42.9
AI Score
VS
RNAZ Wins

RNAZ

47.5
AI Score

Investment Advisor Scores

ICU

43score
Recommendation
HOLD

RNAZ

48score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric ICU RNAZ Winner
Forward P/E 0 0 Tie
PEG Ratio 0 0 Tie
Revenue Growth 82.0% 0.0% ICU
Earnings Growth 0.0% 0.0% Tie
Tradestie Score 42.9/100 47.5/100 RNAZ
Profit Margin 0.0% 0.0% Tie
Beta 1.00 1.00 Tie
AI Recommendation HOLD HOLD Tie

Relative Price Performance (Last 90 Days)

ICU 1M: -14.4% · 3M: -14.4% RNAZ 1M: -52.2% · 3M: -53.6%

Current Technical Phase

ICU

Markdown
Sell / avoid

Price below a falling SMA50 (slope -2.3%), weak momentum, RSI 42

RSI (14): 42.2 · Price: $3.21

RNAZ

Markdown
Sell / avoid

Price below a falling SMA50 (slope -12.0%), weak momentum, RSI 27

RSI (14): 26.9 · Price: $2.84

Fundamentals Snapshot

Metric ICU RNAZ
Market Cap
Forward P/E -1.4 -9.0
Trailing P/E
Revenue (TTM)
Revenue Growth 0.8% 0.0%
Gross Margin 0.9%
Operating Margin -6.2% 0.0%
EPS -1.92 -41.82
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, RNAZ is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.